---
title: "Advanced Biomed Inc. 10-Q Summary: Net income $5.98M, EPS $5.21— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286575108.md"
description: "Advanced Biomed Inc. reported a net income of $5.98M and diluted EPS of $5.21 for the nine months ended Mar 31, 2026, a significant improvement from a net loss of $(2.56) M and EPS of $(2.54) in the same period last year. The company completed R&D on several microfluidic devices and made regulatory progress in China, although commercialization is pending clinical trials and approvals."
datetime: "2026-05-15T13:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286575108.md)
  - [en](https://longbridge.com/en/news/286575108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286575108.md)
---

# Advanced Biomed Inc. 10-Q Summary: Net income $5.98M, EPS $5.21— 10-Q Summary

Advanced Biomed Inc. reported results for the nine months ended Mar 31, 2026, recording net income of $5.98M and diluted earnings per share of $5.21, versus a net loss of $(2.56) M and diluted EPS of $(2.54) for the nine months ended Mar 31, 2025.

**Financial Highlights**

-   Net income: $5.98M for the nine months ended Mar 31, 2026, versus a net loss of $(2.56) M for the nine months ended Mar 31, 2025 (YoY improvement).
-   Diluted earnings per share: $5.21 for the nine months ended Mar 31, 2026, versus $(2.54) for the nine months ended Mar 31, 2025 (YoY improvement).

**Business Highlights**

-   Product development: Completed R&D for multiple microfluidic devices, including A+Pre, AC-1000, A+CellScan and A+SCDrop, and developed the A+PerfusC™ 3D culture system.
-   Regulatory progress: A+Pre and AC-1000 cleared by China's NMPA; several kits and the A+LCGuard product are in registration, review or application stages in China.
-   Commercialization: No product sales yet; commercialization is contingent on clinical trials and regulatory approvals, with sales not expected in the near term.
-   Clinical validation: Completed a 123-case study at Shanghai Pulmonary Hospital reporting 96% sensitivity and 99.9% specificity, supporting product feasibility.
-   Strategic moves: Sold a Hong Kong subsidiary's IP in December 2025 and acquired Acellent HK in April 2026, signaling a pivot toward AI-powered financial audit solutions.

Original SEC Filing: Advanced Biomed Inc. \[ ADVB \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)

## Related News & Research

- [Advanced Biomed Completes AI Acquisition and Leadership Transition](https://longbridge.com/en/news/284946343.md)
- [AleAnna, Inc. Reports First Quarter 2026 Results | ANNA Stock News](https://longbridge.com/en/news/286463118.md)
- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)
- [Ethic Inc. Sells 6,534 Shares of Astera Labs, Inc. $ALAB](https://longbridge.com/en/news/286526653.md)
- [Gotransverse Launches New BI & Analytics Solution to Deliver Real-Time Monetization Intelligence](https://longbridge.com/en/news/286928959.md)